X4 Pharmaceuticals to Announce Financial Results Soon
X4 Pharmaceuticals (NASDAQ: XFOR) is focused on making a significant impact in the realm of rare diseases associated with the immune system. The company plans to share its financial results for the fourth quarter and the complete year ending December 31, 2024, in a conference call scheduled for March 25, 2025. This announcement is highly anticipated as it offers insights into the company’s performance over the year.
Conference Call Details and Live Webcast
The event will kick off at 8:30 a.m. ET, and will include a conference call accessible via phone. Interested parties can join the discussion by dialing 1-800-267-6316 in the U.S. or 1-203-518-9783 internationally, using conference ID: X4PHARMA. Additionally, there will be a live webcast of the event available through the investor relations page on X4 Pharmaceuticals’ website, which will later offer a replay for those who missed it.
Why Attend the Conference Call?
Attending the conference call will provide stakeholders and interested parties with up-to-date information on X4 Pharmaceuticals' financial health and business strategy. Corporate updates are essential for investors looking to understand how the company plans to navigate the evolving landscape of immunology and rare diseases.
About X4 Pharmaceuticals and Its Innovative Therapies
X4 Pharmaceuticals has established itself as a leader in developing innovative therapies tailored for patients with rare immune system disorders. By focusing on overcoming severe unmet medical needs, X4 uses its knowledge in CXCR4 biology to create game-changing therapies. Notably, the company has brought mavorixafor, an oral CXCR4 antagonist, to market under the brand name XOLREMDI, which serves its first indication.
Expansion of Clinical Trials
The company is not resting on its laurels. They are actively evaluating new potential applications for mavorixafor and conducting a pivotal global Phase 3 clinical trial named 4WARD. This trial targets individuals with specific chronic neutropenic disorders, demonstrating X4's commitment to advancing treatment options for patients across the globe.
Commitment to Patients and the Community
Headquartered in Boston, the dedication of X4 Pharmaceuticals goes beyond just the development of medications; it extends to a broader commitment to improve patient lives. Their approach is patient-centric, focusing on understanding the needs of those with rare diseases and how best to address them through tailored therapies.
Contact Details for Stakeholders
For those looking to connect with X4 Pharmaceuticals for more information, the company has made it easy to reach their investor relations team. Daniel Ferry, Managing Director at LifeSci Advisors, can be contacted at (617) 430-7576 or via email. Additionally, Rhiannon Jeselonis from Ten Bridge Communications is available for media inquiries. Both contacts are vital points of communication for investors and stakeholders alike.
Frequently Asked Questions
What are the financial results being announced?
X4 Pharmaceuticals will report their financial performance for the fourth quarter and the entire year ending December 31, 2024.
When will the earnings conference call take place?
The conference call is scheduled for March 25, 2025, at 8:30 a.m. ET.
How can I access the conference call?
You can access the call by dialing 1-800-267-6316 in the U.S. and 1-203-518-9783 for international callers, using conference ID: X4PHARMA.
Where can I find more information about X4 Pharmaceuticals?
For additional details, please visit X4 Pharmaceuticals' official website where further updates and resources are available.
What is the significance of mavorixafor?
Mavorixafor is a breakthrough therapy developed by X4 Pharmaceuticals for patients suffering from rare diseases linked to the immune system.
